43 related articles for article (PubMed ID: 10614063)
21. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
Schmoelzer I; de Campo A; Pressl H; Stelzl H; Dittrich P; Oettl K; Wascher TC
Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):176-81. PubMed ID: 15789278
[TBL] [Abstract][Full Text] [Related]
22. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study.
Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
Diabetes Metab Res Rev; 2004; 20(6):472-8. PubMed ID: 15386822
[TBL] [Abstract][Full Text] [Related]
23. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
24. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Rosak C; Hofmann U; Paulwitz O
Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
[TBL] [Abstract][Full Text] [Related]
25. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Linnebjerg H; Park S; Kothare PA; Trautmann ME; Mace K; Fineman M; Wilding I; Nauck M; Horowitz M
Regul Pept; 2008 Nov; 151(1-3):123-9. PubMed ID: 18675854
[TBL] [Abstract][Full Text] [Related]
26. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
27. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion.
Mauerhoff T; Ketelslegers JM; Lambert AE
Diabete Metab; 1986 Feb; 12(1):34-8. PubMed ID: 3084315
[TBL] [Abstract][Full Text] [Related]
28. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose.
Ceriello A; Taboga C; Tonutti L; Giacomello R; Stel L; Motz E; Pirisi M
Diabetologia; 1996 Apr; 39(4):469-73. PubMed ID: 8777997
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cirrhosis receiving glucose.
Moreau R; Chagneau C; Heller J; Chevenne D; Langlet P; Deltenre P; Hillaire S; Lefilliatre P; Pateron D; Sogni P; Valla D; Lebrec D
Scand J Gastroenterol; 2001 Mar; 36(3):303-8. PubMed ID: 11305519
[TBL] [Abstract][Full Text] [Related]
30. Potentiation by previous nutrients of glibenclamide-induced insulin release in man. An effect which is counteracted by meal-induced retardation of drug absorption.
Grill V; Efendić S; Regitz G
Scand J Clin Lab Invest; 1986 Oct; 46(6):527-32. PubMed ID: 3095909
[TBL] [Abstract][Full Text] [Related]
31. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
32. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Rosak C; Haupt E; Walter T; Werner J
Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
[TBL] [Abstract][Full Text] [Related]
33. Effects of glibenclamide on postprandial coagulation activation.
Ioannidis I; Tsoukala C; Panayotopoulou C; Skrapari I; Maglara E; Anastasopoulou Y; Mandalaki T; Katsilambros N
Nutr Metab Cardiovasc Dis; 1999 Aug; 9(4):204-7. PubMed ID: 10614063
[TBL] [Abstract][Full Text] [Related]
34. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
35. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.
Raptis SA; Hatziagelaki E; Dimitriadis G; Draeger KE; Pfeiffer C; Raptis AE
Exp Clin Endocrinol Diabetes; 1999; 107(6):350-5. PubMed ID: 10543411
[TBL] [Abstract][Full Text] [Related]
36. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]